Short answer · Medically reviewed summary · Last updated: 2023-07-13
Sepiapterin reductase deficiency is a rare genetic disorder that affects the production of neurotransmitters in the brain. It is caused by mutations in the SPR gene, which encodes the enzyme sepiapterin reductase.
What is the prevalence of Sepiapterin Reductase Deficiency?
Prevalence of Sepiapterin Reductase Deficiency: how many people are affected worldwide, differences by sex and region, with sources.
Sepiapterin reductase deficiency is a rare genetic disorder that affects the production of neurotransmitters in the brain. It is caused by mutations in the SPR gene, which encodes the enzyme sepiapterin reductase. This enzyme is involved in the synthesis of tetrahydrobiopterin (BH4), a cofactor required for the production of several neurotransmitters, including dopamine, serotonin, and norepinephrine.
The prevalence of sepiapterin reductase deficiency is currently unknown, as it is a very rare condition. However, it is estimated to affect less than 1 in 1 million individuals worldwide. The disorder is thought to be underdiagnosed due to its rarity and the lack of awareness among healthcare professionals.
Symptoms of sepiapterin reductase deficiency can vary widely but often include developmental delay, intellectual disability, movement disorders, and behavioral problems. Early diagnosis and treatment are crucial to manage the symptoms and improve the quality of life for affected individuals.
Research and advancements in genetic testing have contributed to a better understanding of sepiapterin reductase deficiency. Ongoing studies aim to determine the exact prevalence and identify potential treatment options for this rare disorder.
